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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 94, Revision 2 
(FGE.94Rev2): Consideration of aliphatic amines and amides evaluated in 
an addendum to the group of aliphatic and aromatic amines and amides 
evaluated by the JECFA (68
th
 meeting)
1
 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a 
group of 12 aliphatic amines and amides evaluated by the JECFA at the 68
th
 meeting in 2007. This revision is 
required owing to additional toxicity data on 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-
acrylamide [FL-no: 16.090]. The substances were evaluated through a stepwise approach that integrates 
information on structure-activity relationships, intake from current uses, toxicological threshold of concern and 
available data on metabolism and toxicity. The Panel agrees with JECFA conclusion “No safety concern at 
estimated levels of intake as flavouring substances” based on the MSDI approach for all substances considered 
in this FGE. Besides the safety assessment of these flavouring substances, the specifications for the materials of 
commerce have been considered and for all 12 substances, the information is adequate. 
© European Food Safety Authority, 2014 
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SUMMARY  
Following a request from the European Commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver a scientific opinion to 
the Commission on the implications for human health of chemically defined flavouring substances 
used in or on foodstuffs in the Member States. In particular, the CEF Panel was requested to consider 
the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring 
substances assessed since 2000, and to decide whether no further evaluation is necessary, as laid down 
in Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
In Flavouring Group Evaluation 94, Revision 1 (FGE.94Rev1), the EFSA considered 12 aliphatic 
amines and amides evaluated by the JECFA at the 68
th
 meeting. This revision 2 is made due to 
additional toxicity data received on 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-
acrylamide [FL-no: 16.090] that were requested in the previous opinion.  
The Panel concluded that no supporting Flavouring Group Evaluation was available for the substances 
in the present FGE.  
Genotoxicity data from in vitro and in vivo studies were available for seven [FL-no: 16.090, 16.095, 
16.098, 16.099, 16.102, 16.103 and 16.111] of the flavouring substances and the results did not 
indicate any concern for genotoxicity of the substances in this flavouring group. 
In the previous version of FGE.94 (FGE.94Rev1), the Panel concluded that it could agree with the 
way the application of the Procedure has been performed by the JECFA for 11 substances. For one 
substance [FL-no: 16.090] no adequate NOAEL was available. A new 90-day study has now become 
available for [FL-no: 16.090] and a NOAEL to provide an adequate margin of safety can be derived. 
For 10 of the 12 substances, use levels have been provided by the Industry. Based on the use levels, 
the mTAMDI figures calculated for nine substances [FL-no: 16.090, 16.095, 16.098, 16.099, 16.102, 
16.103, 16.104, 16.111 and 17.035] are above the threshold of concern for their structural classes. For 
these nine substances more reliable data are needed. On the basis of such data the flavouring 
substances should be reconsidered using the Procedure. For the remaining two substances [FL-no: 
16.100 and 16.101], use levels are needed to calculate the mTAMDIs in order to identify those 
flavouring substances that need more refined exposure assessment. 
In order to determine whether the conclusion for the 12 JECFA evaluated substances can be applied to 
the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications are available for all 12 substances.   
For all 12 substances [FL-no: 16.090, 16.095, 16.098, 16.099, 16.100, 16.101, 16.102, 16.103, 16.104, 
16.105, 16.111 and 17.035] the Panel agrees with the JECFA conclusion “No safety concern at 
estimated levels of intake as flavouring substances” based on the MSDI approach. 
Flavouring Group Evaluation 94 Revision 2 
 
EFSA Journal 2014;12(4):3622 3 
TABLE OF CONTENTS 
Abstract .................................................................................................................................................... 1 
Summary .................................................................................................................................................. 2 
Background as Provided by the European Commission .......................................................................... 4 
Terms of Reference as Provided by the European Commission .............................................................. 4 
Assessment ............................................................................................................................................... 5 
1. History of the Evaluation of the Substances in the Present FGE ..................................................... 6 
2. Presentation of the Substances in the JECFA Flavouring Group .................................................... 7 
2.1. Description .............................................................................................................................. 7 
2.1.1. JECFA Status ...................................................................................................................... 7 
2.1.2. EFSA Considerations ......................................................................................................... 7 
2.2. Isomers .................................................................................................................................... 7 
2.2.1. Status .................................................................................................................................. 7 
2.2.2. EFSA Considerations ......................................................................................................... 7 
2.3. Specifications .......................................................................................................................... 7 
2.3.1. Status .................................................................................................................................. 7 
2.3.2. EFSA Considerations ......................................................................................................... 7 
3. Intake Estimation ............................................................................................................................. 7 
3.1. Status ....................................................................................................................................... 7 
3.2. EFSA Considerations .............................................................................................................. 7 
4. Genotoxicity Data .......................................................................................................................... 11 
4.1. Genotoxicity Studies – Text Taken from the JECFA (JECFA, 2008a) ................................ 11 
4.2. Genotoxicity Study on [FL-no: 16.111] ................................................................................ 12 
4.3. EFSA Considerations ............................................................................................................ 13 
5. In Vitro Hydrolysis Study on [FL-no: 16.111] .............................................................................. 13 
6. 90-Day Studies on [FL-no: 16.090, 16.095 and 16.111] ............................................................... 14 
6.1. 90-Day Dietary Toxicity Study in Crl:CD (SD) Rats on Cyclopropanecarboxamide, N-
[(2E)-3,7-dimethyl-2,6-octadien-1-yl]- [FL-no: 16.095] ................................................................... 14 
6.2. 90-Day Oral (by Gavage) Toxicity Study in Crl:CD (SD) Rats on Glycine, N-[[(1R,2S,5R)-
5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]-, ethyl ester [FL-no: 16.111] ............................... 14 
6.3. 14-Day and 90-Day Dietary Study in Rats on 3-(3,4 Dimethoxyphenyl)-N-[2-(3,4 
dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] ...................................................................... 15 
7. Application of the Procedure ......................................................................................................... 17 
7.1. Application of the Procedure to Aliphatic Amines and Amides Substances by the JECFA 
(JECFA, 2008a) ................................................................................................................................. 17 
7.2. EFSA Considerations ............................................................................................................ 18 
Conclusion .............................................................................................................................................. 18 
References .............................................................................................................................................. 27 
Appendix ................................................................................................................................................ 31 
APPENDIX A. Use Levels and mTAMDI .......................................................................................... 31 
Abbreviations ......................................................................................................................................... 33 
 
Table 1: Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 
 2008b) .................................................................................................................................. 8 
Table 2: Genotoxicity Data (in vitro / in vivo) evaluated by JECFA (JECFA, 2008a) ................... 20 
Table 3: Additional Genotoxicity Data on N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide 
  ........................................................................................................................................... 23 
Table 4: Additional Genotoxicity Data on N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxamide 
  ........................................................................................................................................... 23 
Table 5: Summary of Safety Evaluation by the JECFA (JECFA, 2008a) ....................................... 24 
Table 6: Normal and Maximum use levels (mg/kg) available for JECFA evaluated Substances ... 31 
Table 7: Estimated intakes based on the MSDI- and the mTAMDI approach ................................ 32 
Flavouring Group Evaluation 94 Revision 2 
 
EFSA Journal 2014;12(4):3622 4 
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 2008
4
 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5
. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6
. 
On 24 May 2012, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing 
Aids(CEF) adopted a scientific opinion on Flavouring Group Evaluation 94, Revision 1 
(FGE.94Rev1): Consideration of aliphatic amines and amides evaluated in an addendum to the group 
of aliphatic and aromatic amines and amides evaluated by JECFA (68
th
 meeting).  
The Panel concluded that: “For one substance [FL-no: 16.090] additional toxicity data are still needed 
before the evaluation can be finalised. Besides the safety assessment of these flavouring substances, 
the specifications for the materials of commerce have also been consiered and for one substance, [FL-
no: 16.090], the composition of the stereoisomeric mixture has to be specified”. 
The requested data on 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-
no: 16.090] have now been submitted by the applicant.  
The Commission requests EFSA to finalise its safety assessment on [FL-no: 16.090] within nine 
months from the receipt of this letter. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to finalise its safety 
assessment on [FL-no: 16.090] in accordance with Commission Regulation (EC) No 1565/2000. 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting 
the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the 
Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and 
repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p, 1-
161. 
6 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. 
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ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the “EFSA Procedure”. This Procedure 
is based on the Opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA 
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65
th
 meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram (µg)/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the 
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Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per 
day would not be expected to present a safety concern. The Committee recommended that the 
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended 
to include the last step on the right-hand side of the original procedure (“Do the condition of use result 
in an intake greater than 1.5 µg per day?”)” (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro, 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1. History of the Evaluation of the Substances in the Present FGE  
In FGE.94, which contains a group of 12 aliphatic amines and amides, the Panel considered that 
additional toxicity data were needed for three substances [FL-no: 16.090, 16.095 and 16.111] before 
they could be evaluated as flavouring substances, as no adequate toxicity study from which a no 
observed adverse effect level (NOAEL) could be established was available, neither on the substances 
themselves nor on supporting substances. 
In first revision of FGE.94 (FGE.94Rev1) new 90-day studies had been provided for [FL-no: 16.095 
and 16.111] and NOAELs to provide adequate margins of safety could be derived. Furthermore, new 
metabolism and genotoxicity data had been provided for [FL-no: 16.111]. Finally, information on the 
stereoisomeric composition had been provided for three substances [FL-no: 16.090, 16.102 and 
16.104] and ID tests and information on solubility in ethanol had been provided for two substances 
[FL-no: 16.100 and 16.101] (EFFA, 2010; Flavour Industry, 2012). 
FGE Opinion adopted Link No. of substances 
FGE.94 23 September 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1338.htm 12 
FGE.94Rev1 24 May 2012 http://www.efsa.europa.eu/en/efsajournal/pub/2747.htm 12 
FGE.94Rev2 26 March 2014   
The present revision of the FGE is due to additional toxicity data provided for the substance 3-(3,4-
dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090]. The data provided 
are a 14-day range finding study and a 90-day dietary study (Bauter, 2013a; Bauter, 2013b). 
Furthermore, information on the composition of the stereoisomeric mixture has been provided for [FL-
no: 16.090] (Flavour Industry, 2013). 
New information were also provided on the stereoisomeric composition of [FL-no: 16.090] (EFFA, 
2014). 
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2. Presentation of the Substances in the JECFA Flavouring Group 
2.1. Description 
2.1.1. JECFA Status 
The JECFA has evaluated a group of 12 flavouring substances consisting of aliphatic and aromatic 
amines and amides at their 68
th
 meeting (JECFA, 2007). 
2.1.2. EFSA Considerations 
All of the JECFA evaluated substances are in the Register and this consideration therefore deals with 
these 12 substances. The Panel concluded that there are no supporting substances from other FGEs for 
these 12 aliphatic amines and amides. 
2.2. Isomers 
2.2.1. Status 
The following five substances [FL-no: 16.102, 16.103, 16.104, 16.105 and 16.111] have one or more 
chiral centres. Two substances can exist as geometrical isomers [FL-no: 16.090 and 16.095]. 
2.2.2. EFSA Considerations 
Adequate information on the isomeric composition is available for all 12 substances. For the three 
stereoisomeric substances [FL-no: 16.095, 16.105 and 16.111], the CAS register number (CASrn) is 
considered to specify the stereoisomeric composition (Table 1). 
2.3. Specifications 
2.3.1. Status 
The JECFA specifications are available for all substances (JECFA, 2008b). 
2.3.2. EFSA Considerations 
The European Flavour Industry has submitted specifications for all 12 substances commercially used 
in Europe (EFFA, 2006; Flavour Industry, 2004; Flavour Industry, 2006a; Flavour Industry, 2006b; 
Flavour Industry, 2007; Flavour Industry, 2008; Flavour Industry, 2006c). Although the JECFA 
specifications are available, the specifications used in this consideration are those submitted by the 
Industry. See Table 1. The specifications are considered adequate for all 12 substances. 
3. Intake Estimation 
3.1. Status 
For all 12 substances evaluated through the JECFA Procedure intake data are available for the EU. 
3.2. EFSA Considerations 
For 10 JECFA evaluated substances [FL-no: 16.090, 16.095, 16.098, 16.099, 16.102, 16.103, 16.104, 
16.105, 16.111 and 17.035] normal and maximum use levels have been provided by the Flavour 
Industry in accordance with the Commission Regulation (EC) No 1565/2000 (EC, 2000; EFFA, 2006; 
Flavour Industry, 2004; Flavour Industry, 2006a; Flavour Industry, 2006b; Flavour Industry, 2006c; 
Flavour Industry, 2007; Flavour Industry, 2008) (Appendix A, Table A.1). Based on the normal use 
levels, mTAMDI figures (see Table 7) can be calculated (for calculation of mTAMDI figures, see e.g. 
FGE.03, Annex II (EFSA, 2004). 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2008b) 
FL-no 
JECFA
-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity (e) 
EFSA comments /  
Reference for 
specifications 
16.090 
1777 
3-(3,4-Dimethoxyphenyl)-
N-[2-(3,4-
dimethoxyphenyl)-ethyl]-
acrylamide 
 
4310 
 
69444-90-2 
Solid 
C21H25NO5 
371.43 
Practically 
insoluble or 
insoluble 
Slightly soluble 
 
127.9 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
(Flavour Industry, 
2006b). 95 % (E)-
isomer (EFFA, 2014). 
16.095 
1779 
Cyclopropanecarboxamide, 
N-[(2E)-3,7-dimethyl-2,6-
octadien-1-yl]- 
 
4267 
 
744251-93-2 
Solid 
C14H23NO 
221.00 
Insoluble 
Soluble 
146 (at 1 hPa) 
53 
IR NMR 
98 % 
n.a. 
n.a. 
 
(Flavour Industry, 
2004). 
16.098 
1767 
N-(1-Propylbutyl)-1,3-
benzodioxole-5-
carboxamide 
 
4232 
 
745047-51-2 
Solid 
C15H21NO3 
263.34 
Insoluble 
Sparingly 
soluble 
 
116 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
(Flavour Industry, 
2006c). 
16.099 
1768 
N-(2,4-Dimethoxy-
benzyl)-N'-(2-pyridin-2-yl-
ethyl)-oxalamide 
 
4233 
 
745047-53-4 
Solid 
C18H21N3O4 
343.38 
Insoluble 
Sparingly 
soluble 
 
123 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
(Flavour Industry, 
2006c).  
[FL-no: 16.099, 
16.100 and 16.101] 
should be named by 
the same nomenclature 
principles. 
 
16.100 
1769 
N1-(2-Methoxy-4-
methylbenzyl)-N2-(2-(5-
methylpyridin-2-
yl)ethyl)oxalamide 
 
4234 
 
745047-94-3 
Solid 
C19H23N3O3 
341.41 
Insoluble 
Sparingly 
soluble 
- 
132 - 133 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
(Flavour Industry, 
2008).  
[FL-no: 16.099, 
16.100 and 16.101] 
should be named by 
the same nomenclature 
principles. 
16.101 
1770 
N1-(2-Methoxy-4-
methylbenzyl)-N2-(2-
(pyridin-2-
yl)ethyl)oxalamide 
 
4231 
 
745047-97-6 
Solid 
C18H21N3O3 
327.38 
Insoluble 
Sparingly 
soluble 
- 
128 - 129 
IR NMR 
99 % 
n.a. 
n.a. 
 
(Flavour Industry, 
2008).  
[FL-no: 16.099, 
16.100 and 16.101] 
should be named by 
the same nomenclature 
principles. 
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Table 1:  Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2008b) 
FL-no 
JECFA
-no 
EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility (a) 
Solubility in 
ethanol (b) 
Boiling point, °C (c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity (e) 
EFSA comments /  
Reference for 
specifications 
16.102 
1772 
2,3,4,5,6-Pentahydroxy-N-
(2-hydroxyethyl)-
hexanamide  
4254 
 
686298-93-1 
Solid 
C8H7NO7 
239.22 
Soluble 
Soluble 
 
99 - 100 
IR NMR MS 
99 % 
n.a. 
1.562 
 
(Flavour Industry, 
2008). Only one 
diastereomer 
(2R,3S,4S,5R) 
(Flavour Industry, 
2012). Register name 
to be changed to 
(2R,3S,4S,5R)-
2,3,4,5,6-
Pentahydroxy-N-(2-
hydroxyethyl)hexanam
ide. 
16.103 
1774 
Propanamide, 2-hydroxy-
N-(2-hydroxyethyl)- 
 
4256 
 
5422-34-4 
Liquid 
C5H11NO3 
133.15 
Soluble 
Moderate 
380 
 
IR NMR MS 
99 % 
1.481-1.491 
1.185-1.196 
 
(Flavour Industry, 
2008). 
16.104 
1775 
2-[(2-
Hydroxypropanoyl)amino]
ethyl dihydrogen 
phosphate 
 
 
 
782498-03-7 
Solid 
C5H12NO6 
213.13 
Soluble 
Moderate 
 
200 
IR NMR MS 
95 % 
n.a. 
1.521 
 
(EFFA, 2006; Flavour 
Industry, 2008). 
Racemate (EFFA, 
2010). 
16.105 
1773 
(2R,3S,4S,5R)-2-
[(2,3,4,5,6-
Pentahydroxyhexanoyl)am
ino]ethyl dihydrogen 
phosphate 
 
4255 
 
791807-20-0 
Solid 
C8H18NO10P 
319.21 
Soluble 
Moderate 
 
130 
IR NMR MS 
95 % 
n.a. 
1.76 
 
(EFFA, 2006; Flavour 
Industry, 2008). 
16.111 
1776 
Glycine, N-[[(1R,2S,5R)-
5-methyl-2-(1-
methylethyl)cyclohexyl]ca
rbonyl]-, ethyl ester. 
 
4309 
 
68489-14-5 
Solid 
C15H27NO3 
269.38 
Practically 
insoluble 
Soluble 
151 (2.7 hPa) 
80-82 
IR NMR MS 
99 % 
n.a. 
n.a. 
 
(Flavour Industry, 
2007). 
17.035 
1771 
4-Amino-butyric acid 
 
 
 
56-12-2 
Solid 
C4H9NO2 
103.12 
Slightly soluble 
Practically 
insoluble 
 
200 
IR NMR MS 
100 % 
n.a 
n.a. 
 
(Flavour Industry, 
2006a). 
(a): Solubility in water, if not otherwise stated. 
(b): Solubility in 95 % ethanol, if not otherwise stated. 
(c): At 1013.25 hPa, if not otherwise stated. 
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(d): At 20°C, if not otherwise stated. 
(e): At 25°C, if not otherwise stated. 
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4. Genotoxicity Data 
4.1. Genotoxicity Studies – Text Taken7 from the JECFA (JECFA, 2008a) 
In vitro and in vivo genotoxicity testing has been performed on six flavouring substances [FL-no: 
16.090, 16.098, 16.099, 16.102, 16.103 and 16.111] in this group. The results of these studies are 
summarised in Table 2 and described below.  
In vitro 
N-(1-Propylbutyl)-1,3-benzodioxole-5-carboxamide ([FL-no: 16.098], 2,3,4,5,6-pentahydroxy-N-(2-
hydroxyethyl)-hexanamide ([FL-no: 16.102], propanamide, 2-hydroxy-N-(2-hydroxyethyl)- ([FL-no: 
16.103] and 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] 
were tested in Salmonella typhimurium TA98, TA100, TA102, TA1535 and TA1537 and Escherichia 
coli WP2uvrA at concentrations up to 5000 μg/plate, with and without S9 activation. There was no 
evidence of an increase in revertants (Uhde, 2004; Verspeek-Rip, 2004a; Verspeek-Rip, 2004b; 
Zhang, 2004a).  
N-(2,4-dimethoxy-benzyl)-N'-(2-pyridin-2-yl-ethyl)-oxalamide [FL-no: 16.099] induced an increase in 
the number of revertants in S. typhimurium TA1535 in the absence (but not in the presence) of 
metabolic activation compared with control values; however, no dose–response was observed, and the 
mean number of revertants was reported to be below historical spontaneous reversion or negative 
control values. When tested under the conditions of the pre-incubation assay at concentrations of up to 
5000 μg/plate, N-(2,4-dimethoxy-benzyl)-N'-(2-pyridin-2-yl-ethyl)-oxalamide [FL-no: 16.099] 
induced an increase in the number of revertants in S. typhimurium TA100 in the presence of metabolic 
activation, but only at a concentration of 62 μg/plate; no dose–response pattern was observed, and no 
significant increases in the number of revertants were reported in the absence of metabolic activation 
at concentrations of up to 5000 μg/plate. Moreover, N-(2,4-dimethoxy-benzyl)-N'-(2-pyridin-2-yl-
ethyl)-oxalamide [FL-no: 16.099] consistently tested negative in several other strains of S. 
typhimurium (TA98 and TA1537) and in E. coli WP2uvrA in both the absence and presence of 
metabolic activation, in both plate incorporation and pre-incubation assays, at concentrations of up to 
5000 μg/plate. Given the lack of a dose-dependent response, non-reproducibility of results and the fact 
that the number of revertants was below historical control values, it was concluded that N-(2,4-
dimethoxy-benzyl)-N'-(2-pyridin-2-yl-ethyl)-oxalamide [FL-no: 16.099] was non-mutagenic (Zhang, 
2005a). 
Glycine, N-[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]-, ethyl ester [FL-no: 
16.111] induced a slight increase in the number of revertants in S. typhimurium TA100 and TA1535 in 
the absence of metabolic activation compared with control values; however, the increase was not 
statistically significant. In a set of confirmatory experiments, S. typhimurium TA100 and TA1535 
were re-tested at concentrations of 0, 2000, 3000, 4000 or 5000 μg/plate without metabolic activation 
(Table 2). The study reported an increase in revertant colonies in strain TA1535 that was reproducible 
and, at the highest concentration tested, was significantly above in-house historical controls. The 
report concluded that N-[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]-, ethyl ester 
[FL-no: 16.111] was weakly mutagenic to TA1535 under the test conditions. In contrast, increases 
observed in the revertant colonies in S. typhimurium TA100, although statistically significant, were 
small and did not follow a dose–response pattern. Moreover, glycine, N-[[(1R,2S,5R)-5-methyl-2-(1-
methylethyl)cyclohexyl]carbonyl]-, ethyl ester [FL-no: 16.111] consistently tested negative in several 
other strains of S. typhimurium (TA98 and TA1537) and in E. coli WP2uvrA in both the absence and 
presence of metabolic activation, at concentrations of up to 5000 μg/plate (Thompson, 2005). 
N-(1-Propylbutyl)-1,3-benzodioxole-5-carboxamide [FL-no: 16.098] and N-(2,4-dimethoxy-benzyl)-
N'-(2-pyridin-2-yl-ethyl)-oxalamide [FL-no: 16.099] produced no evidence of genotoxicity at 0, 21, 
                                                     
7 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
FGE has been removed. 
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62, 190, 560, 1670 or 5000 μg/ml in standard chromosomal aberration assays in Chinese hamster 
ovary cells cultured with and without S9 metabolic activation (Zhang, 2004b; Zhang, 2005b). 
In vivo 
In a standard mouse micronucleus bone marrow assay, groups of 21 male Swiss albino (CD-1) mice 
per dose were injected intraperitoneally with 0, 175, 350 or 700 mg N-(1-propylbutyl)-1,3-
benzodioxole-5-carboxamide [FL-no: 16.098]/kg bw. At 24, 36 and 48 hours following dose 
administration, seven mice from each group were killed, and their femoral bone marrow was 
harvested, fixed and stained. No statistically significant differences were observed in the number of 
polychromatic erythrocytes with micronuclei between the test groups and the negative control (Pucaj, 
2004a).  
In a standard mouse micronucleus bone marrow assay using the same protocol as described above, 
groups of 21 male Swiss albino (CD-1) mice per dose were injected intraperitoneally with 0, 200, 400 
or 800 mg N-(2,4-dimethoxy-benzyl)-N'-(2-pyridin-2-yl-ethyl)-oxalamide [FL-no: 16.099]/kg bw. At 
24, 36 and 48 hours following dose administration, seven mice from each group were killed, and their 
femoral bone marrow was harvested, fixed and stained. No statistically significant differences were 
observed in the number of polychromatic erythrocytes with micronuclei between the test groups and 
the negative control (Pucaj, 2004b).  
In a similar standard mouse micronucleus bone marrow assay, male NMRI BR mice (five per group) 
were administered aqueous 2,3,4,5,6-pentahydroxy-N-(2-hydroxyethyl)-hexanamide [FL-no: 16.102] 
at 0 (negative or positive control) or 2000 mg/kg bw via gavage. Femoral bone marrow was isolated at 
24 or 48 hours post-administration. Treatment and control mice showed no difference in the ratio of 
polychromatic to normochromatic erythrocytes. 2,3,4,5,6-Pentahydroxy-N-(2-hydroxyethyl)-
hexanamide [FL-no: 16.102] showed no mutagenic potential in the mouse micronucleus assay 
(Buskens, 2004).  
Employing the same standard mouse micronucleus bone marrow assay as used above, male NMRI BR 
mice (five per group) were administered aqueous propanamide, 2-hydroxy-N-(2-hydroxyethyl)- [FL-
no: 16.103] at 0 (negative or positive control) or 2000 mg/kg bw via gavage. Femoral bone marrow 
was isolated 24 or 48 hours after administration. Treated and control mice showed no difference in the 
ratio of polychromatic to normochromatic erythrocytes. Propanamide, 2-hydroxy-N-(2-hydroxyethyl)- 
[FL-no: 16.103] showed no mutagenic potential in the mouse micronucleus assay (Buskens, 2004). 
Conclusion on genotoxicity  
On the weight of evidence, negative results were obtained with the flavouring agents of this group 
when tested in in vitro mutation assays in S. typhimurium and E. coli, as well as in mammalian cells. 
Negative results were also obtained in in vivo micronucleus assays. 
For a summary of in vitro / in vivo genotoxicity data considered by the JECFA see Table 2. 
4.2. Genotoxicity Study on [FL-no: 16.111]  
A Mouse Lymphoma Assay for glycine, N-[[(1R,2S,5R)-5-methyl-2-(1-methylethyl) 
cyclohexyl]carbonyl]-, ethyl ester [FL-no: 16.111] (Flanders, 2006) was submitted after the 
publication of FGE.94.  
The study was conducted according to an adequate design to assess the potential mutagenicity of the 
test material on the thymidine kinase, TK +/-, locus of the L5178Y mouse lymphoma cell line 
(Flanders, 2006). L5178Y TK +/- 3.7.2c mouse lymphoma cells (heterozygous at the thymidine kinase 
locus) were treated with the test material at eight dose levels, in duplicate, together with vehicle 
(solvent) and positive controls. The entire experiment was repeated to confirm the result of the first 
experiment. Four hours exposures were used both with and without activation in Experiment 1. In 
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Experiment 2, the exposure time without activation was increased to 24 hours. The dose range of test 
material, plated for expression of mutant colonies, was selected following the results of a preliminary 
cytotoxicity test and was 42.03 to 672.5 μg/ml in the absence of metabolic activation and 84.06 to 
1008.75 μg/ml in the presence of metabolic activation for the first experiment. For the second 
experiment the dose range plated for expression of mutant colonies was 10.51 to 504.38 μg/ml without 
metabolic activation and 42.03 to 672.5 μg/ml with metabolic activation. 
The maximum dose level used was limited by test material induced cytotoxicity. A precipitate of test 
material was observed at 1345 μg/ml during the course of the study. The vehicle (solvent) controls had 
mutant frequency values that were considered acceptable for the L5178Y cell line at the TK +/- locus. 
The positive control materials induced marked increases in the mutant frequency indicating the 
satisfactory performance of the test and of the activity of the metabolising system.  
The test material did not induce any statistically significant or concentration-related increases in the 
mutant frequency at any dose level, either with or without metabolic activation, in either the first or 
the second experiment incorporating dose levels that exhibited optimum levels of cytotoxicity.  
Study results are presented in Table 3. 
4.3. EFSA Considerations 
Genotoxicity data from in vitro studies are available for seven substances [FL-no: 16.090, 16.095, 
16.098, 16.099, 16.102, 16.103 and 16.111] and in vivo studies were available for four substances [FL-
no: 16.098, 16.099, 16.102 and 16.103] of the 12 flavouring substances evaluated by the JECFA. 
The Panel noted that conflicting positive results were obtained for N-(2,4-dimethoxy-benzyl)-N'-(2-
pyridin-2-yl-ethyl)-oxalamide [FL-no: 16.099] in the one study by (Zhang, 2005a) when tested in the 
S. typhimurim TA1535 and TA100. However, no concentration–related response was observed, the 
positive results with TA1535 and TA100 were not reproducible and concomitantly, the tests with 
TA98 and TA1537 were consistently negative (JECFA, 2008a). The Panel concluded that the 
available data did not raise concern about genotoxicity in the Ames test. 
For the consideration in FGE.94 on cyclopropanecarboxamide, N-[(2E)-3,7-dimethyl-2,6-octadien-1-
yl]- [FL-no: 16.095] an additional genotoxicity study was provided by the Industry (Next Century 
Incorporated, 2004) after the JECFA evaluated the substance at the 68
th
 meeting (JECFA, 2007). In 
this study, the substance was tested in a bacterial reverse mutation test using S. typhimurium strains 
TA97a, TA98, TA100, TA1535, and E. coli strain WP2uvra with and without metabolic activation. It 
was concluded to be negative for the induction of mutagenicity (see Table 4).  
Glycine, N-[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]-, ethyl ester [FL-no: 
16.111] did not induce gene mutations at the thymidine kinase locus in L5178Y cells in the Mouse 
Lymphoma Assay (Flanders, 2006). 
Overall, the Panel considered that the available data did not raise concern with respect to genotoxicity. 
5. In Vitro Hydrolysis Study on [FL-no: 16.111]  
The hydrolysis of glycine, N-[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]-, ethyl 
ester [FL-no: 16.111] was studied in artificial pancreatic juice and rat liver homogenate (Poet et al., 
2005). Based on the disappearance of the employed substrate, [FL-no: 16.111] was hydrolysed in 
artificial pancreatic juice with a half-life of 43 ± 14.7 min and a first order loss rate (K) of 1.06 ± 
0.426 hour
-1
.  In 20 fold-diluted liver homogenate the disappearance of [FL-no: 16.111] was 
considerably faster (half-life: 0.802 ± 0.191 min). However, the potential hydrolysis products p-
menthane-3-carboxylic acid, glycine ethylester and glycine were only detected at trace levels. This 
indicates that the disappearance of [FL-no: 16.111], under the employed in vitro conditions, is due to 
the hydrolysis of the ethyl ester bond rather than the hydrolysis of the amide bond.  
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This stability of the amide bond is in agreement with data provided for N-benzonitrile-p-menthan-3-
carboxamide, [FL-no: 16.117]. This structurally related substance was not hydrolysed when incubated 
with pooled hepatic microsomes from male rats or male humans under conditions in which hydrolytic 
enzymes were shown to be active (Sipes and Kong, 2012). 
In conclusion, the Panel considers that the candidate substance [FL-no: 16.111] cannot be expected to 
be metabolised to innocuous products.  
6. 90-Day Studies on [FL-no: 16.090, 16.095 and 16.111] 
Three 90-day studies requested in first version of this FGE have been submitted for [FL-no: 16.090, 
16.095 and 16.111] by the Industry. 
6.1. 90-Day Dietary Toxicity Study in Crl:CD (SD) Rats on Cyclopropanecarboxamide, N-
[(2E)-3,7-dimethyl-2,6-octadien-1-yl]- [FL-no: 16.095] 
A 90-day dietary toxicity study followed by a 28-day recovery period was performed with 
cyclopropanecarboxamide, N-[(2E)-3,7-dimethyl-2,6-octadien-1-yl]- [FL-no: 16.095] in rats (Bauter, 
2011). The study was performed according to OECD Guideline 408 under GLP. The dose levels tested 
were 0, 11, 110 and 1100 mg/kg diet, equal to mean daily exposures of 0, 0.7, 7.3, and 73.3 mg/kg 
bw/day in the male rats and of 0, 0.8, 8.1, and 80.1 mg/kg bw/day in the female rats. Each test group 
consisted of 10 animals per sex. Recovery groups were included for the control and high dose groups 
as well. Clinical observations, functional observation battery and motor activity were recorded. The 
feed homogeneity was checked by dietary chemical analysis. Data on body weight and individual food 
consumption were collected throughout the in-life phase of the study. Blood samples were taken for 
complete haematological, clinical chemical and serological analyses. At study termination, body 
weight, organ and tissue weights were recorded after macroscopical examination and complete 
histopathology was performed on the animals of the control and highest dose groups. No substance-
related effects were found implying that the highest dose group is the NOAEL of 1100 mg/kg diet 
which is equal to approximately 73 mg N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxamide/kg 
bw/day in male rats. 
6.2. 90-Day Oral (by Gavage) Toxicity Study in Crl:CD (SD) Rats on Glycine, N-
[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]-, ethyl ester [FL-no: 
16.111] 
A 90-day oral toxicity study by gavage in Crl:CD (SD) rats (males and females) followed by 14-day 
recovery period was performed with glycine, N-[[(1R,2S,5R)-5-methyl-2-(1-
methylethyl)cyclohexyl]carbonyl]-, ethyl ester [FL-no: 16.111] (Kirkpatrick, 2011). The study was 
performed according to OECD Guideline  408 under GLP. The substance was administered at doses of 
0, 25, 75, 225 and 675 mg/kg bw/day to 10 animals/sex/dose group via gavage. Recovery groups were 
included for the control and high dose groups. The following parameters were evaluated: daily clinical 
observation, weekly recording of individual body weight and food consumption while clinical 
chemistry, hematology, blood clotting parameters and urinalysis were done at study termination and at 
the end of the recovery period. A modified Irwin test, performed before start and on week 12 of the 
study, was conducted in order to evaluate any potential effect on the central nervous system. 
Ophtalmology examination was performed on week 1 and week 12 of the study. Complete necropsies 
were conducted on all animals and selected organs were weighted. Selected tissues were examined 
microscopically from all animals in the control and the 675 mg/kg bw/day groups at the primary 
necropsy. Kidney, liver, heart and gross lesions were examined microscopically from all animals at the 
scheduled necropsies. Sections of kidneys were also evaluated for presence of α2u-globulin by 
immunohistochemistry. Spermatogenic endpoints (motility, morphology and numbers) were evaluated 
for all males at the scheduled necropsies. 
  Increase in the number ofmonocytes (in males), neutrophils , and white blood cells  in both genders 
were observed in the high-dose treated group. These increases declined after the recovery period. 
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Lower hematocrit values were seen at 225 and 675 mg/kg bw/day in the males but not in the females. 
However, lower hematocrit, accompanied by decrease in hemoglobin, red blood cell count, mean 
corpuscular volume and increase in red cell distribution width were observed after the recovery period 
in both sexes at 675 mg/kg/ bw/day.  
At 675 mg/kg bw/day, in both genders it was observed an increase in serum creatinine, urea nitrogen, 
triglycerides, total urine volume and a reduction in serum albumin/globulin ratios, chloride levels and 
specific gravity. An increase in calcium level was observed only in males. 
These changes were not present after the recovery period.  
At gross macroscopy, enlarged kidneys with rough surface were observed in one male and pale kidney 
was reported for one female rat at 675 mg/kg bw/day, which correlated with the histopathological 
observation of renal tubular degeneration. An increase in liver and kidney weight was observed in 
male and female rats at 675 mg/kg bw/day, though this finding was no longer present after the 
recovery period.  
Test substance-related microscopic findings were noted in the kidney (tubular degeneration and 
dilatation, interstitial fibrosis and tubular epithelium vacuolation) and in the liver (periportal 
hepatocellular vacuolation and centrilobular hepatocellular hypertrophy) in both male and female rats 
and in the heart of females (increase in incidence of cardiomyopathy) at 675 mg/kg bw/day. 
Furthermore, tubular hyaline droplets were observed in male kidney at all doses. However, this finding 
was not dose-related and considered to correlate with the increase in male rat specific α-2µ-globulin 
observed at immunohistohemical investigation. Microscopic changes in the kidney, liver and heart 
were also present after the recovery period, but they were less severe.  
Renal changes observed in both genders and cardiomyopathy observed only in female rats at 675 
mg/kg bw/day were considered adverse effects. Haematological changes observed at 225 and 675 
mg/kg bw/day were also considered adverse as they were dose- related. Red cells changes were also 
present after a recovery period of 14 days at the dose of 675 mg/kg bw/day. Therefore, the Panel 
established a NOAEL of 75 mg/kg bw/day. 
6.3. 14-Day and 90-Day Dietary Study in Rats on 3-(3,4 Dimethoxyphenyl)-N-[2-(3,4 
dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] 
In a 14-day dietary palatability and general toxicity study, groups of male and female Hsd:SD
®
 rats 
(5/sex/dietary intake level) were fed a diet that contained 0 (dietary control), 3000, 6000 and 12 000 
mg 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] per kg 
feed (Bauter, 2013a). These dietary levels were calculated to correspond to an actual intake of 275, 
542 and 1075 mg/kg bw/day for males and 276, 553 and 902 mg/kg bw/day for females. Clinical 
observations were recorded daily and body weights and food consumption observations were made on 
day 0, 3, 7, 10 and 14. No mortality was observed throughout the course of the study and the general 
condition of the rats was unremarkable. Body weight, weight gain and food efficiency was reduced for 
females fed diets with 6000 and 12 000 mg test substance/kg feed, and for males fed 12 000 mg/kg 
feed when compared to controls (Bauter, 2013a). 
A 90-day dietary study was performed with 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-
ethyl]-acrylamide [FL-no: 16.090] (Bauter, 2013b). The study was performed according to OECD 
Guideline 408 and the requirements of US FDA GLP. Four groups (10/sex/dietary intake level) of 
male and female CRL Sprague-Dawley CD®IGS rats were fed a diet that contained 0 (dietary 
control), 350, 1050 and 4200 mg of 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-
acrylamide per kg feed. The levels corresponded to a calculated daily intake of 0, 23, 69 and 279 
mg/kg bw for males and 0, 26, 82 and 340 mg/kg bw for females. Ophthalmologic examinations were 
conducted prior to the initiation of the study and on day 88. Clinical observations of toxicity were 
performed on day 0 and weekly until sacrifice. Animals were weighed on day 0 at the start of the study 
and weekly thereafter. Near the end of the study period (day 78 - 81), functional observations of 
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sensory reactivity to different stimuli, grip strength and motor activity were assessed. Food 
consumption and efficiency were measured and calculated weekly. Blood chemistry and haematology 
were performed on blood drawn via sublingual bleed during week 12 after overnight fast. Urine was 
collected during the 15 hours prior to the blood draw. At termination of the study, all survivors were 
sacrificed and subject to full necropsy. 
Four animals died during the course of the study. On day 64, a single male rat of the 350 mg/kg feed 
group was found dead for indeterminate cause (no clinical signs). On day 14, 35 and 75, three female 
rats in the 4200 mg/kg feed group, respectively, were found dead. The clinical observations for the 
three dead female rats included intermittent slight tremors, vocalisation, prone posture and moderate to 
extreme ataxia, clonic convulsion, palor, tremors, twitches,  hyperactivity and irregular respiration in 
the female that died on day 14. The female deaths are attributable to the very high concentration of the 
test material in the diet. All other clinical signs were regarded by the CEF Panel as incidental and not 
related to 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide in the diet. 
All surviving animals included in the study were normal upon ophthalmic examination on day 88, 
therefore the test substance was not considered an ocular toxicant. Significant and dose-dependent 
reductions in body weight and body weight gain were reported for the 4200 mg/kg feed female group 
throughout the study. The male rats and the 1050 and 350 mg/kg feed female rats showed body 
weights and body weight gains that were overall comparable to the concurrent controls. Food 
consumption and efficiency were comparable among groups receiving the test material and controls 
with minor variations that were incidental. Functional observational battery results were comparable 
between test and control groups as were motor activity measurements. Notable differences in 
haematology parameters were reported for the 1050 and 4200 mg/kg feed female group. Statistically 
significant decreases in haemoglobin and haematocrit levels and increased red cell width were 
reported and correlated to increases in haematopoiesis and erythroid hyperplasia in the spleen and 
bone marrow. Additionally, for the 1050 and 4200 mg/kg feed groups significant dose-dependent 
changes in haematological parameters were observed, including increased absolute reticulocyte 
counts, decreased red blood cell counts, increased mean corpuscular volume (for females) and 
increased mean corpuscular haemoglobin (only in the 4200 mg/kg female group). The study director 
associated these findings with regenerative anemia in response to 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-
dimethoxyphenyl)-ethyl]-acrylamide in the diet. Coagulation parameters were comparable between 
test and control groups for both sexes. There were no statistically significant alterations in clinical 
chemistry parameters measured when test groups were compared to both concurrent and historical 
controls. 
Organ weight and ratio measurements showed statistically significant differences in adrenal, spleen, 
liver and kidney of male and female rats in the 4200 mg/kg group when compared to controls.  
Relevant microscopic changes were reported for the 4200 mg/kg feed male and female groups. 
Tan/brown, granular cytoplasmic proximal tubular epithelial pigment of the kidneys was observed in 
7/10 males and 6/7 females. Minimal globular pigment was noted in the cytoplasm of the liver Kupffer 
cells in 8/10 males and 5/7 females and a slight increase in hematopoiesis with brown/tan, globular, 
pigment in the cytoplasm of fixed macrophages of the splenic red pulp in all males and females of the 
4200 mg/kg feed group. There was also a slight increase in the cytoplasmic cortical vacuolisation of 
the adrenals in 7/10 males and 7/7 females of the 4200 mg/kg group. For  7/7 females of the same dose 
group it was observed a slight-moderate brain mineralisation and vacuolisation of the neutrophil grey 
area of the forebrain and a slight erythroid hyperplasia of the bone marrow (Bauter, 2013b). 
Based on the toxicological endpoints described above, and with special consideration of the dose- 
dependent effects on hematological parameters, the Panel decided that the no-adverse-effect level 
(NOAEL) for 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide in the diet is 
350 mg/kg feed, which corresponds to an estimated daily intake of  23 and 26 mg/kg bw/day for males 
and females, respectively. 
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7. Application of the Procedure 
7.1. Application of the Procedure to Aliphatic Amines and Amides Substances by the 
JECFA (JECFA, 2008a) 
According to the JECFA five of the substances belong to structural class I and seven to structural class 
III using the decision tree approach presented by Cramer et al. (Cramer et al., 1978). 
The JECFA concluded five aliphatic amines and amides substances [FL-no: 16.102, 16.103, 16.104, 
16.105 and 17.035] at step A3 in the JECFA Procedure – meaning that the substances are expected to 
be metabolised to innocuous products (step 2) and concluded that the intakes for all substances are 
below the thresholds for their structural class I (step A3).  
The remaining seven flavouring substances in this group cannot be predicted to be metabolised to 
innocuous products. The estimated daily per capita intakes of these flavouring substances are below 
the threshold of concern (i.e. 90 μg/person per day) for structural class III, and a No Observed Adverse 
Effect Level (NOAEL) exists to provide an adequate margin of safety to the estimated intake as 
flavouring substances (step B4). 
Step B4.  
For N-(1-propylbutyl)-1,3-benzodioxole-5-carboxamide [FL-no: 16.098] (N-(heptan-4-
yl)benzo[d][1,3]dioxole-5-carboxamide), the no-observed-effect level (NOEL) of 20 mg/kg bw per 
day from a 93-day study in rats (Kot, 2005a) provides an adequate margin of safety (>10 million) in 
relation to the currently estimated level of exposure from its use as a flavouring agent in Europe 
(0.0002 μg/kg body weight (bw) per day) and in the USA (0.002 μg/kg bw per day). 
For N-(2,4-dimethoxy-benzyl)-N'-(2-pyridin-2-yl-ethyl)-oxalamide [FL-no: 16.099] (N1-(2,4-
dimethoxybenzyl)-N2-(2-(pyridin-2-yl)ethyl)-oxalamide), the NOEL of 100 mg/kg bw per day from a 
93-day study in rats (Kot, 2005b) provides an adequate margin of safety (> 33 million) in relation to 
the currently estimated level of exposure from its use as a flavouring agent in Europe (0.0002 μg/kg 
bw per day) and in the USA (0.003 μg/kg bw per day). This NOEL is appropriate for the structurally 
related flavouring agents N1-(2-methoxy-4-methylbenzyl)-N2-(2-(5-methylpyridin-2-
yl)ethyl)oxalamide [FL-no: 16.100] and N1-(2-methoxy-4-methylbenzyl)-N2-(2-(pyridin-2-
yl)ethyl)oxalamide [FL-no: 16.101], because they are also oxalamides and are expected to be 
metabolized by similar pathways. For these structurally related flavouring agents, the NOEL of 100 
mg/kg bw per day provides an adequate margin of safety (500 million) in relation to the currently 
estimated levels of exposure to these flavouring agents in both Europe and the USA (0.0002 μg/kg bw 
per day). 
For glycine, N-[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]-, ethyl ester [FL-no: 
16.111], the NOEL of 8 mg/kg bw per day for the structurally related substance N-ethyl 2-isopropyl-5-
methylcyclohexane carboxamide ([FL-no: 16.013] considered in FGE.86) from a 28-day study in rats 
(Miyata, 1995) provides an adequate margin of safety (> 13 000) in relation to the currently estimated 
level of exposure from its use as a flavouring substance in Europe (0.6 μg/kg bw/day). 
For 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] (N-[2-
(3,4-dimethoxyphenyl)ethyl]-3,4-dimethoxycinnamic acid amide), the NOEL of 8.36 mg/kg bw per 
day for the structurally related N-nonanoyl-4-hydroxy-3-methoxybenzylamide ([FL-no: 16.006] 
considered in FGE.86) from a 90-day study in rats (Posternak et al., 1969) provides an adequate 
margin of safety (> 400 000) in relation to the currently estimated level of exposure from its use as a 
flavouring agent in the USA (0.02 μg/kg bw per day).  
For cyclopropanecarboxamide, N-[(2E)-3,7-dimethyl-2,6-octadien-1-yl]- [FL-no: 16.095], the NOEL 
of 92 mg/kg bw per day from a 28-day study in rats (Merkel, 2005) provides an adequate margin of 
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safety (> 180 000) in relation to the currently estimated level of exposure from its use as a flavouring 
agent in the USA (0.5 μg/kg bw per day). 
The evaluations of the 12 substances are summarised in Table 5: Summary of Safety Evaluation by the 
JECFA (JECFA, 2008a). 
7.2. EFSA Considerations 
In the previous version of FGE.94, the Panel agreed with the way the application of the Procedure has 
been performed by the JECFA for 9 of the 12 aliphatic and aromatic amines and amides. For the 
remaining three substance [FL-no: 16.090; FL-no: 16.095 and FL-no: 16.111] the Panel did not agree 
and concluded that additional toxicity data are needed before it can be evaluated as a flavouring 
substance. 
In the first revision of FGE.94 additional toxicity data had become available for two substances [FL-
no: 16.095 and 16.111]. 
Based on the new data submitted (Bauter, 2011) for cyclopropanecarboxamide, N-[(2E)-3,7-dimethyl-
2,6-octadien-1-yl]- [FL-no: 16.095] a NOAEL of 73.3 mg/kg bw/day could be established. When 
comparing this NOAEL at step B4 in the Procedure to the estimated exposure based on the MSDI (61 
µg per capita per day, corresponding to 1 µg /kg bw/day) an adequate margin of safety of 7  10
4
 can 
be calculated. 
Based on the new data submitted (Kirkpatrick, 2011) for glycine, N-[[(1R,2S,5R)-5-methyl-2-(1-
methylethyl)cyclohexyl]carbonyl]-, ethyl ester [FL-no: 16.111] a NOAEL of 75 mg/kg bw/day could 
be established. When comparing this NOAEL at step B4 in the Procedure to the estimated exposure 
based on the MSDI (37 µg per capita per day, corresponding to 0.6 µg /kg bw/day) an adequate 
margin of safety of 12  10
4
 can be calculated. 
After the publication of FGE.94Rev1 additional toxicity data have become available for the substance 
[FL-no: 16.090]. 
Based on the new data (Bauter, 2013b) submitted for 3-(3,4-dimethoxyphenyl)-N-[2-(3,4-
dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090] a NOAEL of 23.4 mg/kg bw/day could be 
established. When comparing this NOAEL at step B4 in the Procedure to the estimated exposure based 
on the MSDI (1.3 µg per capita per day, corresponding to 0,02 µg /kg bw/day) an adequate margin of 
safety of 1.2  10
6
 can be calculated. 
Thus the Panel concludes that all 12 substances can be considered to be of no safety concern at their 
estimated dietary intake based on the MSDI approach. 
CONCLUSION 
In Flavouring Group Evaluation 94, Revision 1 (FGE.94Rev1) the EFSA considered a group of 12 
flavouring substances consisting of aliphatic and aromatic amines and amides evaluated by the JECFA 
at the 68
th
 meeting (JECFA, 2007).  
The present revision of FGE.94, FGE.94Rev2, includes the assessment of additional toxicity data for 
3-(3,4-dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide [FL-no: 16.090]. 
The Panel concluded that no supporting FGE was available for the substances in the present FGE.  
Genotoxicity data from in vitro and in vivo studies were available for seven [FL-no: 16.090, 16.095, 
16.098, 16.099, 16.102, 16.103 and 16.111] of the 12 flavouring substances evaluated by the JECFA 
and the results did not indicate any concern for genotoxicity of the substances in this flavouring group. 
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In FGE.94 the Panel agreed with the way the application of the Procedure has been performed by the 
JECFA for nine of 12 substances, but for three substances [FL-no: 16.090, 16.095 and 16.111] no 
adequate NOAEL were available.  In the first revision of FGE.94 additional toxicity data had become 
available for two substances [FL-no: 16.095 and 16.111] and NOAELs to provide adequate margins of 
safety were derived. 
Since then a 90-day study has also been provided for [FL-no: 16.090] and a NOAEL could be 
established to provide an adequate margin of safety. 
For 10 of the 12 substances, use levels have been provided by the Industry. Based on these use levels 
the mTAMDI figures calculated for nine substances [FL-no: 16.090, 16.095, 16.098, 16.099, 16.102, 
16.103, 16.104, 16.111 and 17.035] are above the threshold of concern for their structural classes. For 
these substances more reliable data are needed. On the basis of such data the flavouring substances 
should be reconsidered using the Procedure. Following this procedure additional toxicological data 
might become necessary. For the remaining two [FL-no: 16.100 and 16.101] of the 12 substances, use 
levels are needed to calculate the mTAMDIs in order to identify those flavouring substances that need 
more refined exposure assessment. 
In order to determine whether the conclusion for the JECFA evaluated substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate specifications 
are available for all 12 substances [FL-no: 16.090, 16.095, 16.098, 16.099, 16.100, 16.101, 16.102, 
16.103, 16.104, 16.105, 16.111 and 17.035].  
Thus, for all 12 substances [FL-no: 16.090, 16.095, 16.098, 16.099, 16.100, 16.101, 16.102, 16.103, 
16.104, 16.105, 16.111 and 17.035] the Panel agrees with JECFA conclusion “No safety concern at 
estimated levels of intake as flavouring substances” based on the MSDI approach.
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SUMMARY OF GENOTOXICITY DATA  
Table 2:  Genotoxicity Data (in vitro / in vivo) evaluated by JECFA (JECFA, 2008a) 
FL-no 
JECFA
-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
In vitro 
16.098 
1767 
 
N-(1-Propylbutyl)-1,3-
benzodioxole-5-carboxamide 
 
Reverse 
mutation(a) 
S. typhimurium 
TA98, TA100, 
TA1535 and TA1537   
0, 21, 62, 190, 560, 
1670 or   
5000 µg/plate(b)   
 
Negative(c) (Zhang, 2004a) 
Reverse 
mutation(a) 
E. coli   
WP2uvrA   
0, 21, 62, 190, 560, 
1670 or   
5000 µg/plate(b)   
Negative(c) (Zhang, 2004a) 
Chromosomal 
aberration 
Chinese hamster 
ovary cells 
0, 21, 62, 190, 560, 
1670 or   
5000 µg/ml  
Negative(c) (Zhang, 2004b) 
16.099 
1768 
N-(2,4-Dimethoxy-benzyl)-
N'-(2-pyridin-2-yl-ethyl)-
oxalamide 
 
Reverse 
mutation(a) 
S. typhimurium 
TA98, TA100, 
TA1535 and TA1537   
 
0, 21, 62, 190, 560 or 
1670  
 µg/plate 
Weakly 
positive/ 
negative(c,d) 
(Zhang, 2005a) 
Reverse 
mutation(a) 
E. coli   
WP2uvrA   
 
0, 21, 62, 190, 560, 
1670 or   
5000 µg/plate 
Negative(c) (Zhang, 2005a) 
Chromosomal 
aberration 
Chinese hamster 
ovary cells 
0, 21, 62, 190, 560, 
1670 or   
5000 µg/plate 
Negative(c) (Zhang, 2005b) 
16.102 
1772 
2,3,4,5,6-Pentahydroxy-N-(2-
hydroxyethyl)-hexanamide 
 
Reverse 
mutation 
S. typhimurium 
TA98, TA100, 
TA1535 and TA1537   
0, 3,(e) 10, (e) 33, (e) 
100, 333, 1000,  
3330 or 5000 
µg/plate    
Negative(c) (Verspeek-Rip, 2004a) 
Reverse 
mutation 
E. coli   
WP2uvrA   
 
0, 3, 10, 33, 100, 
333, 1000,  3330 or 
5000 µg/plate   
 
Negative(c) (Verspeek-Rip, 2004a) 
16.103 
1774 
Propanamide, 2-hydroxy-N-
(2-hydroxyethyl)- 
 
Reverse 
mutation 
S. typhimurium 
TA98, TA100, 
TA1535 and TA1537   
0, 3, (e) 10, (e) 33, (e) 
94, 310, 940,  3140 
or 4720 µg/plate   
Negative(c) (Verspeek-Rip, 2004b) 
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Table 2:  Genotoxicity Data (in vitro / in vivo) evaluated by JECFA (JECFA, 2008a) 
FL-no 
JECFA
-no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
  
   Reverse 
mutation 
E. coli   
WP2uvrA   
0, 3, 10, 33, 94, 310, 
940,  3140 or 4720 
µg/plate   
Negative(c) (Verspeek-Rip, 2004b) 
16.090 
1777 
3-(3,4-Dimethoxyphenyl)-N-
[2-(3,4-dimethoxyphenyl)-
ethyl]-acrylamide 
 
Reverse 
mutationa 
S. typhimurium 
TA98, TA100, 
TA102, TA1535 and 
TA1537   
0, 31.6, 100, 316, 
1000 or 3160 
µg/plate 
Negative(c) (Uhde, 2004) 
16.111 
1776 
Glycine, N-[[(1R,2S,5R)-5-
methyl-2-(1-
methylethyl)cyclohexyl]carb
onyl]-, ethyl ester 
 
Reverse 
mutation 
S. typhimurium 
TA98, TA100,  
TA1535 and TA1537  
 
0, 50, 150, 500, 
1500, 2000(f), 3000(f), 
4000(f) or 5000(f) 
µg/plate 
Weakly 
positive(c,g) 
(Thompson, 2005) 
Reverse 
mutation 
E. coli   
WP2uvrA  
0, 50, 150, 500, 1500 
or 5000 µg/plate 
Negative(c) (Thompson, 2005) 
In vivo 
16.098 
1767 
N-(1-Propylbutyl)-1,3-
benzodioxole-5-carboxamide 
 
Micronucelus 
induction 
Swiss albino (CD-1) 
mice 
0, 175, 350 or 700 
mg/kg bw(h) 
Negative (Pucaj, 2004a) 
16.099 
1768 
N-(2,4-Dimethoxy-benzyl)-
N'-(2-pyridin-2-yl-ethyl)-
oxalamide 
 
Micronucelus 
induction 
Swiss albino (CD-1) 
mice 
0, 200, 400 or 800 
mg/kg bw(h) 
Negative (Pucaj, 2004b) 
16.102 
1772 
2,3,4,5,6-Pentahydroxy-N-(2-
hydroxyethyl)-hexanamide   
 
Micronucelus 
induction 
NMRI BR mice 0 or 2000 mg/kg 
bw(i) 
Negative (Buskens, 2004) 
16.103 
1774 
(2R)-2-Hydroxy-N-(2-
hydroxyethyl)propanamide 
 
Micronucelus 
induction 
NMRI BR mice 0 or 2000 mg/kg 
bw(i) 
Negative (Buskens, 2004) 
(a): Plate incorporation assay and preincubation assay. 
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(b): The maximum concentration tested was 1670 μg/plate except for S. typhimurium TA100 in the plate incorporation assay, for S. typhimurium TA98 and TA100 and E. coli WP2uvrA in the 
preincubation assay without S9 (9000 × g supernatant from rat liver) and for S. typhimurium TA98, TA1535 and TA1537 and E. Coli WP2uvrA in the preincubation assay with S9, because 
of precipitation. 
(c): With and without metabolic activation. 
(d): In the plate incorporation assay, S. typhimurium TA1535 tested positive at concentrations of 21, 190 and 1670 μg/plate, but only without S9. In the preincubation assay, S. typhimurium 
TA100 tested positive only at 62 μg/plate and only with S9. 
(e): For S. typhimurium TA100 only. 
(f): S. typhimurium TA100 and TA1535 tested without S9 using both plate incorporation and preincubation methods. 
(g): Weak incidence of reverse mutation observed in S. typhimurium TA100 and TA1535. All other strains showed no evidence of mutagenicity. 
(h): Test material administered via single intraperitoneal injection. 
(i): Test material administered via single gavage dose. 
 
 
Flavouring Group Evaluation 94 Revision 2 
 
EFSA Journal 2014;12(4):3622 23 
 
Table 3:  Additional Genotoxicity Data on N-[(ethoxycarbonyl)methyl]-p-menthane-3-carboxamide 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula Test System Test Object  Route Dose Reported 
Result  
Reference  
16.111 
1776 
Glycine, N-[[(1R,2S,5R)-5-
methyl-2-(1-
methylethyl)cyclohexyl]carbo
nyl]-, ethyl ester 
 
Mouse Lymphoma L5178Ytk+/- 
mouse lymphoma 
cells 
Oral 42.03 to 672.5 µg/ml 
 
84.06 to 1008.75 µg/ml 
 
Negative(a) 
 
Negative(b) 
(Flanders, 2006) 
Mouse Lymphoma L5178Ytk+/- 
mouse lymphoma 
cells 
Gavage 10.51 to 504.38 µg/ml 
 
42.03 to 672.5 µg /ml 
 
Negative(a) 
 
Negative(b) 
(Flanders, 2006) 
(a): Without metabolic activation. 
(b): With metabolic activation. 
 
 
 
Table 4:  Additional Genotoxicity Data on N-3,7-dimethyl-2,6-octadienyl cyclopropylcarboxamide 
FL-no 
JECFA-
no 
EU Register name 
JECFA name 
Structural formula End-point Test system Concentration Results Reference 
16.095 
1779 
 
Cyclopropanecarboxamide, N-
[(2E)-3,7-dimethyl-2,6-
octadien-1-yl]-  
Reverse 
mutation 
S. typhimurium 
TA97a, TA98, 
TA100, TA1535   
0, 5, 10, 50, 100, 500, 
1000, 2000, 2500 or 
5000 µg/plate  
 
Negative(a) (Next Century 
Incorporated, 2004) 
Reverse 
mutation 
E. coli   
WP2uvrA   
0, 50, 100, 500, 1000 
or 2000 µg/plate   
 
Negative(a) (Next Century 
Incorporated, 2004) 
(a): With and without metabolic activation. 
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SUMMARY OF SAFETY EVALUATIONS 
Table 5:  Summary of Safety Evaluation by the JECFA (JECFA, 2008a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(µg/capita/day) 
Class (b) 
Evaluation 
procedure path (c) 
Outcome on the 
named compound 
[(d) or (e)] 
EFSA conclusion on 
the named 
compound 
(Procedure steps, 
intake estimates, 
NOAEL, 
genotoxicity) 
EFSA conclusion 
on the material of 
commerce 
16.102 
1772 
2,3,4,5,6-Pentahydroxy-
N-(2-hydroxyethyl)-
hexanamide  
24 
13 
Class I 
A3: Intake below 
threshold 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.103 
1774 
Propanamide, 2-
hydroxy-N-(2-
hydroxyethyl)-  
24 
10 
Class I 
A3: Intake below 
threshold 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.104 
1775 
2-[(2-
Hydroxypropanoyl)ami
no]ethyl dihydrogen 
phosphate 
 
12 
5 
Class I 
A3: Intake below 
threshold 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.105 
1773 
(2R,3S,4S,5R)-2-
[(2,3,4,5,6-
Pentahydroxyhexanoyl)
amino]ethyl dihydrogen 
phosphate 
 
12 
3 
Class I 
A3: Intake below 
threshold 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
17.035 
1771 
4-Amino-butyric acid 
 
0.12 
0.1 
Class I 
A3: Intake below 
threshold 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.090 
1777 
3-(3,4-
Dimethoxyphenyl)-N-
[2-(3,4-
dimethoxyphenyl)-
ethyl]-acrylamide 
 
1.3 
1 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
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Table 5:  Summary of Safety Evaluation by the JECFA (JECFA, 2008a) 
FL-no 
JECFA-no 
EU Register name Structural formula EU MSDI (a)  
US MSDI 
(µg/capita/day) 
Class (b) 
Evaluation 
procedure path (c) 
Outcome on the 
named compound 
[(d) or (e)] 
EFSA conclusion on 
the named 
compound 
(Procedure steps, 
intake estimates, 
NOAEL, 
genotoxicity) 
EFSA conclusion 
on the material of 
commerce 
16.095 
1779 
Cyclopropanecarboxami
de, N-[(2E)-3,7-
dimethyl-2,6-octadien-
1-yl]- 
 
61 
31 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.098 
1767 
N-(1-Propylbutyl)-1,3-
benzodioxole-5-
carboxamide 
 
0.012 
0.1 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.099 
1768 
N-(2,4-Dimethoxy-
benzyl)-N'-(2-pyridin-2-
yl-ethyl)-oxalamide 
 
0.012 
0.2 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.100 
1769 
N1-(2-Methoxy-4-
methylbenzyl)-N2-(2-
(5-methylpyridin-2-
yl)ethyl)oxalamide  
0.012 
0.01 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.101 
1770 
N1-(2-Methoxy-4-
methylbenzyl)-N2-(2-
(pyridin-2-
yl)ethyl)oxalamide  
0.012 
0.01 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
16.111 
1776 
Glycine, N-
[[(1R,2S,5R)-5-methyl-
2-(1-
methylethyl)cyclohexyl]
carbonyl]-, ethyl ester.  
37 
34 
Class III 
B3: Intake below 
threshold, B4: 
Adequate NOAEL 
exists 
d No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level 
of intake based on 
the MSDI approach. 
(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)= µg/capita/day. 
(b): Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
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(c): Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d): No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e): Data must be available on the substance or closely related substances to perform a safety evaluation. 
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APPENDIX  
Appendix A.  Use Levels and mTAMDI 
Normal and maximum use levels provided by the Flavour Industry (EC, 2000; EFFA, 2006; Flavour Industry, 2004; Flavour Industry, 2006a; Flavour 
Industry, 2006b; Flavour Industry, 2006c; Flavour Industry, 2007; Flavour Industry, 2008) in accordance with the Commission Regulation (EC) No 
1565/2000 (EC, 2000). 
The normal and maximum use levels are shown in Table A.1. Based on these normal use levels mTAMDI figures can be calculated (see Table A.2). 
Table 6:  Normal and Maximum use levels (mg/kg) available for JECFA evaluated Substances 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
16.090 3 
10 
- 
- 
5 
10 
- 
- 
- 
- 
10 
20 
- 
- 
10 
50 
- 
- 
- 
- 
- 
- 
- 
- 
5 
20 
- 
- 
3 
20 
5 
25 
10 
30 
5 
10 
16.095 0,01 
0,05 
0,01 
0,05 
0,1 
0,5 
- 
- 
- 
- 
1 
5 
- 
- 
0,1 
0,5 
0,01 
0,05 
0,01 
0,05 
- 
- 
- 
- 
0,01 
0,05 
- 
- 
1 
5 
1 
5 
0,01 
0,05 
0,01 
0,05 
16.098 1 
3 
2 
4 
- 
- 
1 
3 
1 
3 
- 
- 
- 
- 
1 
2 
1 
3 
1 
3 
- 
- 
- 
- 
5 
10 
- 
- 
- 
- 
- 
- 
5 
10 
1 
3 
16.099 1 
3 
2 
4 
- 
- 
1 
3 
1 
3 
- 
- 
- 
- 
1 
2 
1 
3 
1 
3 
- 
- 
- 
- 
5 
10 
- 
- 
- 
- 
- 
- 
5 
10 
1 
3 
16.102 50 
200 
50 
200 
50 
200 
- 
- 
- 
- 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
16.103 50 
200 
50 
200 
50 
200 
- 
- 
- 
- 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
50 
200 
16.104 5 
15 
- 
- 
5 
15 
5 
15 
- 
- 
5 
15 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
5 
15 
- 
- 
5 
15 
5 
15 
5 
15 
- 
- 
16.105 - 
- 
5 
15 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
5 
15 
- 
- 
- 
- 
- 
- 
5 
15 
- 
- 
- 
- 
- 
- 
5 
15 
- 
- 
16.111 10 
300 
10 
200 
10 
150 
10 
200 
10 
200 
10 
200 
10 
50 
20 
200 
10 
100 
10 
100 
- 
- 
- 
- 
- 
- 
20 
300 
10 
50 
10 
400 
50 
350 
10 
200 
17.035 30 
100 
30 
100 
20 
100 
- 
- 
- 
- 
30 
100 
30 
100 
50 
300 
20 
200 
- 
- 
- 
- 
- 
- 
- 
- 
30 
200 
30 
200 
40 
300 
20 
100 
30 
100 
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Table 7:  Estimated intakes based on the MSDI- and the mTAMDI approach 
FL-no EU Register name MSDI – EU 
( g/capita/day) 
MSDI – USA 
( g/capita/day) 
mTAMDI 
( g/person/day) 
Structural 
class 
Threshold of 
concern 
(µg/person/day) 
16.102 2,3,4,5,6-Pentahydroxy-N-(2-hydroxyethyl)-hexanamide 24 13 27000 I 1800 
16.103 Propanamide, 2-hydroxy-N-(2-hydroxyethyl)- 24 10 27000 I 1800 
16.104 2-[(2-Hydroxypropanoyl)amino]ethyl dihydrogen phosphate 12 5 2700 I 1800 
16.105 (2R,3S,4S,5R)-2-[(2,3,4,5,6-Pentahydroxyhexanoyl)amino]ethyl 
dihydrogen phosphate 
12 3 870 I 1800 
17.035 4-Amino-butyric acid 0.12 0.1 18000 I 1800 
16.090 3-(3,4-Dimethoxyphenyl)-N-[2-(3,4-dimethoxyphenyl)-ethyl]-acrylamide 1.3 1 3000 III 90 
16.095 Cyclopropanecarboxamide, N-[(2E)-3,7-dimethyl-2,6-octadien-1-yl]- 61 31 380 III 90 
16.098 N-(1-Propylbutyl)-1,3-benzodioxole-5-carboxamide 0.012 0.1 470 III 90 
16.099 N-(2,4-Dimethoxy-benzyl)-N'-(2-pyridin-2-yl-ethyl)-oxalamide 0.012 0.2 470 III 90 
16.100 N1-(2-Methoxy-4-methylbenzyl)-N2-(2-(5-methylpyridin-2-
yl)ethyl)oxalamide 
0.012 0.01 ND III 90 
16.101 N1-(2-Methoxy-4-methylbenzyl)-N2-(2-(pyridin-2-yl)ethyl)oxalamide 0.012 0.01 ND III 90 
16.111 Glycine, N-[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]carbonyl]-
, ethyl ester. 
37 34 7400 III 90 
ND: No intake data available 
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ABBREVIATIONS 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF  Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EPA  United States Environmental Protection Agency  
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GLP  Good laboratory practice 
HPRT  Hypoxanthine Phosphoribosyl transferase 
ID  Identity 
IP  Intraperitoneal 
IR  Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
MNBN  Micronucleated Binucleate cells 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NCE  Normochromatic erythrocyte 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL No Observed Effect Level 
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NTP  National Toxicology Program 
PCE  Polychromatic erythrocyte 
RI  Replication Index 
SCE  Sister chromatic exchange 
SCF  Scientific Committee on Food 
UDS  Unscheduled DNA Synthesis 
WHO  World Health Organisation 
